COMAS Medical Technologies AB

Chronic and complex wound care is one of the costliest and most systematically underestimated problems in modern medicine. Diabetic ulcers, pressure sores, difficult post-surgical wounds, infections that do not respond to standard treatments: these conditions affect millions of patients across Europe, generate enormous burdens for healthcare systems, and have a profound impact on the quality of life of those affected. Yet the wound care sector has long been dominated by traditional approaches with significant room for improvement. COMAS Medical Technologies AB has developed a solution that addresses this problem from a novel angle: rather than inventing a completely new technology - with the regulatory risks and development timelines this entails - it combined two already established and internationally approved technologies, cleared by both the FDA and CE MDR, with proprietary software and electronics into an integrated, innovative wound care system. This approach has deep strategic implications. The regulatory validation of the underlying technologies significantly reduces the path required for approval of the combined system, lowering risks and accelerating market access timelines compared to an entirely new medical device. The added value lies in the combination: the way in which the two technologies are orchestrated by COMAS's proprietary software produces a clinical outcome superior to what either could achieve individually, with a synergy that also constitutes the main competitive advantage. The B2B2C model reflects the structure of the medical device market: COMAS sells to healthcare facilities, hospital procurement systems, and wound care specialists, who in turn use the system to treat patients. Clinicians are the gatekeepers of the adoption decision - their trust is earned through solid clinical data and a proposition that concretely improves outcomes relative to the current standard of care. In a sector with a European market worth billions of euros and demand set to grow with an ageing population, COMAS positions itself as a focused innovator bringing a clinically superior solution to a space that needs it.